Rheumatoid Arthritis відкриті
[search 0]
більше

Download the App!

show episodes
 
Rheumatoid arthritis is a chronic long term condition that principally attacks flexible joints, causing painful swelling, stiffness and fatigue. The risk of developing RA is associated with ageing but it also affects adults of working age and is three times more common in women. 56 year old Liz noticed her first symptoms in 1996, when her son was just 2 years old. In this collection, she shares her experiences of living with RA, from early symptoms to drug-controlled remission.
 
B
Biologic Therapy In Rheumatoid Arthritis

1
Biologic Therapy In Rheumatoid Arthritis

rhnews@elsevier.com (Rheumatology News International)

Unsubscribe
Unsubscribe
Щомісяця
 
Biologic Therapy in Rheumatoid Arthritis: Pioneers in Research, is a monthly series of podcasts featuring interviews with today's giants in rheumatology sponsored by Schering-Plough Corporation. In this series brought to you by Rheumatology News International, you will hear some of the greatest scientists in rheumatology describe the exploration of what was then uncharted medical territory. Their words will bring alive the journey of discovery that placed them in the annals of history's grea ...
 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease affecting over 1.3 million Americans and as much as 1% of the worldwide population. The condition can be difficult to diagnose in its early stages because of non-specific early signs and symptoms that mimic many other diseases, and there is no singular confirmatory blood test or physical finding. But the evidence is clear: early diagnosis and treatment lead to improved outcomes for RA patients. Rheumatoid Arthritis: Addre ...
 
Dr. Clifton Bingham from the Johns Hopkins Arthritis Center begins with a review of current best practices, including the issues related to diagnosis. Dr. George Lawry will follow with an overview of the risks and benefits of biologic therapy for patients with RA before Dr. Bingham presents on emerging DMARDs.The second half of the nearly 2 hour presentation covers the subject of comorbidities, presented by Dr. Lawry, on how to recognize comorbidities and how to best manage them. Dr. Bingham ...
 
Loading …
show series
 
Host: Jason Liebowitz, MD Guest: Michael Putman, MD, MSci As evidence-based medicine (EBM) continues to evolve, what do rheumatologists need to know to keep up? Drs. Jason Liebowitz and Michael Putman dive into EBM and its role in the field of rheumatology. Dr. Liebowitz and Dr. Putman are Novartis consultants. 194889 4/22…
 
Dr. Clifton Bingham from the Johns Hopkins Arthritis Center begins with a review of current best practices, including the issues related to diagnosis. Dr. George Lawry will follow with an overview of the risks and benefits of biologic therapy for patients with RA before Dr. Bingham presents on emerging DMARDs.The second half of the nearly 2 hour pr…
 
This sixth podcast program, Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities, features an interview with Professor McInnes. He discusses the current state of knowledge in rheumatoid arthritis and directions for discovery in coming years.rhnews@elsevier.com (Rheumatology News International)
 
This fifth podcast titled Progress and Prognosis: Evaluating Patients’ Responses to Biologic Therapy features a telephone interview with Professor Schett. He discusses differences among the anti-TNF agents in the treatment of rheumatoid arthritis.rhnews@elsevier.com (Rheumatology News International)
 
Professor VonVollenhoven discusses factors which distinguish individual responses by patients with rheumatoid arthritis to various anti-TNF agents. He describes observations of radiologic and clinical progression of illness in subgroups of patients and provides an overview of considerations in choosing one pharmacologic agent over another. Professo…
 
Contemporary research shows that the early diagnosis and treatment of RA can offer patients the possibility of achieving remission. The goal for any patient with early RA should be to achieve remission. If a patient does not already have joint damage, the goal should be a normal acute-phase response and no swollen joints as soon as possible.…
 
Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination …
 
Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini utilized two new technologies -- protein sequencing and cDNA protein coding -- to investigate half a dozen cytokine…
 
Loading …

Короткий довідник